Pharm-136
Pharm-136, also known as 7-methyl-10-hydroxynoribogaminalog, is a serotonin 5-HT 2 receptor agonist and psychedelic drug of the ibogalog family.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Pharm-136, also known as 7-methyl-10-hydroxynoribogaminalog, is a serotonin 5-HT 2 receptor agonist and psychedelic drug of the ibogalog family.
Pharmacodynamics
Pharm-136 acts as a potent serotonin 5-HT 2 receptor agonist, with ( ) values of 0.6 nM (102%) at the serotonin 5-HT 2A receptor, 3.5 nM (52%) at the serotonin 5-HT 2B receptor, and 0.5 nM (101%) at the serotonin 5-HT 2C receptor. The drug showed far lower agonistic potency or was inactive at all other serotonin receptors.
As an agonist of the serotonin 5-HT 2A receptor in vitro, Pharm-136 showed 29-fold greater potency as well as higher efficacy (101% vs. 80%) than psilocin. The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its median effective dose (ED 50 ) was 3.6 mg/kg, compared to 0.38 mg/kg (9.5-fold lower) in the case of psilocybin.
Pharmacokinetics
The preclinical pharmacokinetics of Pharm-136 have been studied.
Chemistry
Pharm-136 is an ibogalog (azepinoindole) derivative and a cyclized tryptamine analogue of the non-hallucinogenic psychoplastogen 7-methylpsilocin.
Synthesis
The chemical synthesis of Pharm-136 has been described.
History
Pharm-136 was patented by Bright Minds Biosciences in 2023. There is interest in Pharm-136 for potential therapeutic use.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370149759 under CC BY-SA 4.0; modifications have been made.